WILMINGTON PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 369 GBX | +0.27% |
|
+2.50% | +11.14% |
| Apr. 26 | Wilmington sells French healthcare business APM for EUR26 million | AN |
| Apr. 26 | Wilmington Sells French Healthcare Unit for EUR26 million | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Consumer Publishing
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +8.43% | 409M | C+ | ||
| +2.20% | 8.29B | A | ||
| +6.90% | 6.43B | B | ||
| +38.86% | 5.08B | - | - | |
| +14.98% | 3.56B | D- | ||
| +21.44% | 3.06B | C- | ||
| +10.72% | 3B | B+ | ||
| -1.11% | 2.42B | - | ||
| +7.85% | 1.71B | - | ||
| +16.89% | 1.64B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- WIL Stock
- Ratings Wilmington plc
